With a white‑blood‑cell count of 10 000 cells/µL (instead of 1 000), what is the most likely diagnosis and initial management for a patient presenting with acute kidney injury, hematuria, proteinuria, and bulky kidneys?

Most Likely Diagnosis: ANCA-Associated Vasculitis (AAV)

With a WBC count of 10,000 cells/µL, acute kidney injury, hematuria, proteinuria, and bulky kidneys, the most likely diagnosis is ANCA-associated vasculitis presenting as rapidly progressive glomerulonephritis (RPGN), and you should immediately initiate immunosuppressive therapy while simultaneously obtaining ANCA serology (MPO and PR3 antibodies) and scheduling a kidney biopsy—but do not delay treatment waiting for these results 1.

Diagnostic Reasoning

The clinical constellation of:

• Acute kidney injury with rapid decline in function
• Glomerular hematuria (blood on dipstick)
• Proteinuria
• Bulky kidneys (suggesting inflammatory infiltration)
• Normal-range WBC count (10,000/µL rules out severe leukopenia or marked leukocytosis)

This presentation is classic for RPGN, with AAV being the most common cause 1. The WBC count of 10,000/µL is actually reassuring—it falls in the middle quintile range, which is associated with better outcomes compared to either leukopenia or marked leukocytosis in AKI patients 2.

Immediate Management Algorithm

Step 1: Exclude Infection (Critical First Step)

Before starting immunosuppression, you must exclude infection with as much certainty as possible 1. This includes:

• Blood cultures
• Urine cultures
• Chest imaging
• Consider procalcitonin levels if sepsis is a concern

Step 2: Obtain Serologies Immediately (Do Not Wait for Results)

Order the following autoimmune panel 1:

• MPO-ANCA and PR3-ANCA (most important)
• Anti-GBM antibodies
• ANA (to evaluate for lupus nephritis)
• Complement levels (C3, C4)

Step 3: Start Immunosuppressive Therapy NOW

If the clinical presentation is compatible with AAV and infection has been reasonably excluded, commence treatment immediately—do not wait for biopsy results or serology to return 1.

Induction Therapy Options:

Choose Cyclophosphamide if:

• Severe GN with serum creatinine >4 mg/dL (>354 µmol/L)
• Limited data support rituximab in this severe setting
• Can consider combination: 2 IV pulses of cyclophosphamide + rituximab 1

Choose Rituximab if:

• Less severe renal impairment (creatinine <4 mg/dL)
• Patient preference to avoid cyclophosphamide toxicity
• Fertility concerns

Plus:

• Glucocorticoids (reduced-dose regimens are now preferred based on PEXIVAS trial data) 1

Step 4: Obtain Kidney Biopsy Soon After Starting Treatment

The biopsy serves two purposes 1:

1. Confirms diagnosis (though treatment shouldn't wait for this)
2. Provides prognostic information (degree of chronicity, percentage of crescents, tubular atrophy)

Biopsy when feasible and no contraindications exist 1.

Critical Pitfalls to Avoid

1. Do NOT delay immunosuppression waiting for biopsy or serology results if clinical presentation strongly suggests AAV—this is the most common error and worsens outcomes 1, 3.

2. Do NOT routinely use plasma exchange in AAV—recent evidence shows it doesn't improve outcomes 1. Exception: If anti-GBM antibodies are also positive (dual-positive disease), then plasma exchange is indicated 1.

3. Do NOT assume all AKI is sepsis-related just because it's common—intrinsic renal disease presenting as AKI has poor outcomes when diagnosis is delayed 3.

4. Do NOT overlook ANCA-negative pauci-immune glomerulonephritis—this can still be AAV and requires the same aggressive treatment 4.

Why This WBC Count Matters

The corrected WBC count of 10,000/µL (versus 1,000/µL) significantly changes the clinical picture. A WBC of 10,000/µL:

• Falls in the medium-low trajectory group, associated with 14.8% 28-day mortality in sepsis patients 5
• Is in the middle quintile, which has the lowest risk for AKI progression and mortality 2
• Makes severe sepsis less likely as the primary driver
• Supports a primary glomerular disease process rather than sepsis-associated AKI

In contrast, marked leukocytosis (>20,000) or leukopenia (<4,000) would suggest sepsis-associated AKI with worse prognosis 5, 2.

Maintenance Therapy (After Induction)

Once remission is achieved, transition to maintenance therapy with 1:

• Rituximab (preferred) OR
• Azathioprine
• Plus low-dose glucocorticoids

The guideline explicitly prefers rituximab for maintenance over azathioprine 1.